Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00136760
Status:
COMPLETED
Last Update Posted:
2015-10-07
First Post:
2005-08-25
Brief Title:
Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia
Sponsor:
Brown University
Organization:
Brown University
Study Overview
Official Title:
Incentives Plus Bupropion for Smoking in Schizophrenics
Status:
COMPLETED
Status Verified Date:
2013-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
There is a high prevalence of smoking among people with schizophrenia and there are few smoking treatment programs for these smokers The aims of this study are to investigate the separate and combined effects of bupropion and a voucher incentive program on smoking in people with schizophrenia
Detailed Description:
There is a high prevalence of smoking among people with schizophrenia and there are few smoking treatment programs for these smokers In this study we are investigating whether the combination of bupropion also called Zyban and Wellbutrin and a behavioral treatment program contingent vouchers can reduce smoking in people with schizophrenia This is a 3-week study aimed to investigate the feasibility of this treatment approach Participants are randomly assigned to bupropion 300 mgday in 2 divided doses or placebo After one week on medication participants are randomly assigned to the active behavioral treatment contingent vouchers or the control treatment non-contingent vouchers Over a 3-week period participants come to the study site about 2-3 times per week and provide information about their recent smoking and nicotine withdrawal symptoms They also give saliva and urine samples that are analyzed for levels of cotinine a nicotine metabolite Participants in the active behavioral treatment group receive gift cards to local grocery stores when their cotinine levels indicate that they have reduced their smoking Participants in the control behavioral treatment group receive gift cards regardless of cotinine level Any participant who significantly reduces their smoking at the end of the trial is followed up 2 and 4 weeks after the end of the trial too see if they have sustained these smoking reductions If we have favorable results from this trial we will expand it into a smoking treatment program
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01-17566-1 | US NIH GrantContract | None | httpsreporternihgovquickSearchR01DA017566 |
| R01DA017566 | NIH | None | None |